Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS.
10.19746/j.cnki.issn.1009-2137.2019.02.032
- Author:
Su-Qing GUO
1
;
Rui SHI
1
;
Yuan-Yuan CHEN
1
;
Shan LIU
1
;
Ying-Hua LI
2
Author Information
1. Department of Hematology, Hengshui Harrison International Peace Hospital, Hengshui 053000, Hebei Province, China.
2. Department of Hematology, Hengshui Harrison International Peace Hospital, Hengshui 053000, Hebei Province, China,E-mail: yinghuali71@163.com.
- Publication Type:Journal Article
- MeSH:
Aged;
Antineoplastic Combined Chemotherapy Protocols;
Azacitidine;
Bone Morphogenetic Proteins;
Decitabine;
administration & dosage;
therapeutic use;
Growth Differentiation Factors;
Hematopoietic Stem Cell Transplantation;
Humans;
Hyaluronan Receptors;
Myelodysplastic Syndromes;
drug therapy;
Treatment Outcome
- From:
Journal of Experimental Hematology
2019;27(2):509-514
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effects of low-dose decitabine on levels of soluble CD44 and GDF11, and hematopoietic function in elderly patients with myelodysplastic syndrome (MDS).
METHODS:Ninety-nine patients with senile myelodysplastic syndrome (MDS) admitted to our hospital from October 2015 to October 2017 were divided into group A, B and C according to their treatment, each with 33 cases.The patients in group A were treated with low-dose decitabine, the patients in group B were treated with usual dose of decitabine, and the patients in group C were treated with low-dose decitabine plus G-GSF, cytarabine, and aclarithromycin. The changes of soluble CD44, GDF11 levels and hematopoietic function (sTfR/E) were compared before and after treatment. The clinical remission rate and adverse reaction rate in 3 groups were analyzed.
RESULTS:Before treatment, the levels of CD44, GDF11 and sTfR/E were not significantly different between the 3 groups (P＞0.05). After treatment, the levels of CD44 and GDF11 were significantly decreased in these groups, while the serum levels of sTfR/E were significantly increased, and there was no significant difference between the 3 groups (P＞0.05). After treatment, the total effective rates of A, B, and C 3 group were 82.3%, 81.8%, and 78.8%, respectively, without statistically significant difference (P＞0.05). During the treatment, the incidence of non-hemotoxic adverse reactions in group A was 8.8%, significantly lower than that in group B and C (30.3%, 27.3%) (P＜0.05, P＜0.05), the incidence of hemotoxic adverse reactions in group A was 39.4%, significantly lower than that 63.6% and 66.7% in group B and C (P＜0.05, P＜0.05).
CONCLUSION:Low-dose decitabine alone is effective in treating elderly patients with MDS as compared with conventional dose and combination therapy, moreover can significantly reduce the levels of CD44 and GDF11, improve hematopoietic function and low the adverse reactions. Thereby the low dose of decitabine may be a new choice for clinical treatment of MDS.
